EGTXEgetis Therapeutics ABEGTX info
$0.88info1.32%24h
Global rank15932
Market cap$256.25M
Change 7d6.74%
YTD Performance56.92%
SP500 benchmarkOutperform
P/E0
P/S0
Revenue$0
Earnings$0
Dividend yield-
Main Sector
Healthcare
Business data

    Egetis Therapeutics AB (EGTX) Stock Overview

    Egetis Therapeutics AB (publ), a pharmaceutical company, focuses on projects in late-stage development for the treatment of serious diseases with unmet medical needs in the orphan drug segment. Its products pipeline includes Aladote, a drug to reduce the risk of acute liver injury associated with acetaminophen/paracetamol poisoning, which is in phase IIb/III clinical trial; and Emcitate, a drug for the treatment of MCT8 deficiency, a highly debilitating rare disease with no available treatment. The company was formerly known as PledPharma AB (publ) and changed its name to Egetis Therapeutics AB (publ) in December 2020. Egetis Therapeutics AB (publ) was incorporated in 2006 and is based in Stockholm, Sweden.

    EGTX Stock Information

    Symbol
    EGTX
    Address
    Klara Norra Kyrkogata 26Stockholm, 111 22Sweden
    Founded
    -
    Trading hours
    -
    Website
    https://www.egetis.com
    Country
    πŸ‡ΈπŸ‡ͺ Sweden
    Phone Number
    46 86 79 72 10

    Egetis Therapeutics AB (EGTX) Price Chart

    -
    Value:-

    Egetis Therapeutics AB Overview: Key Details and Summary

    Stock data
    2024
    Change
    Price
    $0.8758622663651716
    N/A
    Market Cap
    $256.25M
    N/A
    Shares Outstanding
    292.57M
    N/A
    Employees
    25.00
    N/A
    logo
    Facebook Icon
    Twitter Icon
    Linkedin Icon
    Β© 2024 Topstocks.org